JPWO2022098955A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022098955A5 JPWO2022098955A5 JP2023526977A JP2023526977A JPWO2022098955A5 JP WO2022098955 A5 JPWO2022098955 A5 JP WO2022098955A5 JP 2023526977 A JP2023526977 A JP 2023526977A JP 2023526977 A JP2023526977 A JP 2023526977A JP WO2022098955 A5 JPWO2022098955 A5 JP WO2022098955A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- baseline
- patient
- fcrn antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110884P | 2020-11-06 | 2020-11-06 | |
| US63/110,884 | 2020-11-06 | ||
| US202163137972P | 2021-01-15 | 2021-01-15 | |
| US63/137,972 | 2021-01-15 | ||
| US202163173126P | 2021-04-09 | 2021-04-09 | |
| US63/173,126 | 2021-04-09 | ||
| US202163173919P | 2021-04-12 | 2021-04-12 | |
| US63/173,919 | 2021-04-12 | ||
| US202163174423P | 2021-04-13 | 2021-04-13 | |
| US63/174,423 | 2021-04-13 | ||
| US202163175440P | 2021-04-15 | 2021-04-15 | |
| US63/175,440 | 2021-04-15 | ||
| US202163203075P | 2021-07-07 | 2021-07-07 | |
| US202163219155P | 2021-07-07 | 2021-07-07 | |
| US202163203077P | 2021-07-07 | 2021-07-07 | |
| US63/203,077 | 2021-07-07 | ||
| US63/203,075 | 2021-07-07 | ||
| US63/219,155 | 2021-07-07 | ||
| PCT/US2021/058188 WO2022098955A1 (en) | 2020-11-06 | 2021-11-05 | Fcrn antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548858A JP2023548858A (ja) | 2023-11-21 |
| JPWO2022098955A5 true JPWO2022098955A5 (https=) | 2024-11-14 |
| JP2023548858A5 JP2023548858A5 (https=) | 2024-11-14 |
Family
ID=81455198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526977A Pending JP2023548858A (ja) | 2020-11-06 | 2021-11-05 | Ｆｃｒｎ抗体及びその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220144946A1 (https=) |
| EP (1) | EP4240417A4 (https=) |
| JP (1) | JP2023548858A (https=) |
| KR (1) | KR20230117575A (https=) |
| AU (1) | AU2021376364A1 (https=) |
| CA (1) | CA3200972A1 (https=) |
| IL (1) | IL302516A (https=) |
| JO (1) | JOP20230098A1 (https=) |
| MX (1) | MX2023005313A (https=) |
| PH (1) | PH12023551241A1 (https=) |
| TW (1) | TW202233236A (https=) |
| WO (1) | WO2022098955A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240875B2 (en) | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CA3101462A1 (en) | 2018-06-08 | 2019-12-12 | Argenx Bvba | Compositions and methods for treating immune thrombocytopenia |
| KR102921210B1 (ko) | 2018-07-20 | 2026-01-30 | 모멘타 파머슈티컬스 인코포레이티드 | Fcrn 항체 조성물 |
| BR112022013554A2 (pt) | 2020-01-08 | 2022-09-06 | argenx BV | Métodos para tratar distúrbios do pênfigo |
| CA3258000A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE |
| EP4615481A1 (en) * | 2022-11-07 | 2025-09-17 | argenx BV | Methods for treating lupus nephritis using fcrn antagonists |
| WO2024163894A1 (en) * | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| TW202527982A (zh) * | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) * | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250052465A (ko) * | 2015-01-30 | 2025-04-18 | 모멘타 파머슈티컬스 인코포레이티드 | ＦｃＲｎ 항체 및 이의 사용 방법 |
| CA3038894A1 (en) * | 2016-09-28 | 2018-04-05 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| US12240875B2 (en) * | 2017-12-08 | 2025-03-04 | argenx BV | Use of FCRN antagonists for treatment of generalized myasthenia gravis |
| KR102904658B1 (ko) * | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| MX2021000790A (es) * | 2018-07-20 | 2021-07-21 | Momenta Pharmaceuticals Inc | Composiciones de anticuerpos del receptor neonatal para fc y metodos de uso de las mismas. |
| MA53903A (fr) * | 2018-10-16 | 2021-08-25 | UCB Biopharma SRL | Méthode de traitement de la myasthénie grave |
| EP4007605A4 (en) * | 2019-08-01 | 2023-08-16 | Momenta Pharmaceuticals, Inc. | ANTI-FCRN ANTIBODIES AND METHODS OF USE THEREOF |
-
2021
- 2021-11-05 IL IL302516A patent/IL302516A/en unknown
- 2021-11-05 EP EP21890118.9A patent/EP4240417A4/en active Pending
- 2021-11-05 CA CA3200972A patent/CA3200972A1/en active Pending
- 2021-11-05 WO PCT/US2021/058188 patent/WO2022098955A1/en not_active Ceased
- 2021-11-05 TW TW110141386A patent/TW202233236A/zh unknown
- 2021-11-05 PH PH1/2023/551241A patent/PH12023551241A1/en unknown
- 2021-11-05 KR KR1020237018942A patent/KR20230117575A/ko active Pending
- 2021-11-05 JP JP2023526977A patent/JP2023548858A/ja active Pending
- 2021-11-05 US US17/519,811 patent/US20220144946A1/en active Pending
- 2021-11-05 MX MX2023005313A patent/MX2023005313A/es unknown
- 2021-11-05 AU AU2021376364A patent/AU2021376364A1/en active Pending
-
2023
- 2023-05-04 JO JOJO/P/2023/0098A patent/JOP20230098A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103930444B (zh) | 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法 | |
| CN109789194B (zh) | 用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法 | |
| CN109069868B (zh) | 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法 | |
| US20130028891A1 (en) | Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| CA3137682A1 (en) | Anti-cd40 antibodies for use in treatment of t1dm and insulitis | |
| WO2010132683A1 (en) | Methods and compositions for treating lupus | |
| JPWO2022098955A5 (https=) | ||
| US20110229465A1 (en) | Composition for treating disease | |
| US12144859B2 (en) | B cell depleting agent for the treatment of atherosclerosis | |
| US12139546B2 (en) | Methods of treating urea cycle disorders by interfering with glucagon receptor signaling | |
| CA3157797A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
| JP2025168424A (ja) | 急性期の視神経脊髄炎の予防又は治療剤 | |
| WO2023134771A1 (zh) | 抗ctla-4抗体药物组合物及其用途 | |
| JPWO2022221239A5 (https=) | ||
| CN120603605A (zh) | 用于通过施用il-4r拮抗剂改善骨生长的方法 | |
| TW202530264A (zh) | 用於治療多發性硬化症之方法及組合物 | |
| JP2025134967A (ja) | 認知症の予防又は治療剤 | |
| WO2025191459A1 (en) | Use of bispecific anti-egfr/c-met antibodies to treat solid tumors | |
| TH2101002581A (th) | วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn | |
| JPWO2023133280A5 (https=) | ||
| EP0765171A1 (en) | Treatment of autoimmune and inflammatory disorders | |
| NZ619092A (en) | Anti-angptl3 antibodies and uses thereof |